These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19890267)

  • 1. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.
    Fowler JS; Logan J; Azzaro AJ; Fielding RM; Zhu W; Poshusta AK; Burch D; Brand B; Free J; Asgharnejad M; Wang GJ; Telang F; Hubbard B; Jayne M; King P; Carter P; Carter S; Xu Y; Shea C; Muench L; Alexoff D; Shumay E; Schueller M; Warner D; Apelskog-Torres K
    Neuropsychopharmacology; 2010 Feb; 35(3):623-31. PubMed ID: 19890267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain monoamine oxidase A inhibition in cigarette smokers.
    Fowler JS; Volkow ND; Wang GJ; Pappas N; Logan J; Shea C; Alexoff D; MacGregor RR; Schlyer DJ; Zezulkova I; Wolf AP
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14065-9. PubMed ID: 8943061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-MAO A binding of clorgyline in white matter in human brain.
    Fowler JS; Logan J; Ding YS; Franceschi D; Wang GJ; Volkow ND; Pappas N; Schlyer D; Gatley SJ; Alexoff D; Felder C; Biegon A; Zhu W
    J Neurochem; 2001 Dec; 79(5):1039-46. PubMed ID: 11739617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
    Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
    Sacher J; Houle S; Parkes J; Rusjan P; Sagrati S; Wilson AA; Meyer JH
    J Psychiatry Neurosci; 2011 Nov; 36(6):375-82. PubMed ID: 21463543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
    Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
    Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
    Garcia-Miralles M; Ooi J; Ferrari Bardile C; Tan LJ; George M; Drum CL; Lin RY; Hayden MR; Pouladi MA
    Exp Neurol; 2016 Apr; 278():4-10. PubMed ID: 26825854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational neuroimaging: positron emission tomography studies of monoamine oxidase.
    Fowler JS; Logan J; Volkow ND; Wang GJ
    Mol Imaging Biol; 2005; 7(6):377-87. PubMed ID: 16265597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibitors of monoamine oxidase (MAO). 5. 1-Substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site.
    Harfenist M; McGee DP; Reeves MD; White HL
    J Med Chem; 1998 Jun; 41(12):2118-25. PubMed ID: 9622553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
    Celada P; Artigas F
    J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
    Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
    Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of type A monoamine oxidase by coptisine in mouse brain.
    Ro JS; Lee SS; Lee KS; Lee MK
    Life Sci; 2001 Dec; 70(6):639-45. PubMed ID: 11833714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
    Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
    J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
    Bench CJ; Price GW; Lammertsma AA; Cremer JC; Luthra SK; Turton D; Dolan RJ; Kettler R; Dingemanse J; Da Prada M
    Eur J Clin Pharmacol; 1991; 40(2):169-73. PubMed ID: 1906004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
    Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):382-391. PubMed ID: 27633250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of monoamine oxidase-a increases respiration in isolated mouse cortical mitochondria.
    Kalimon OJ; Vekaria HJ; Gerhardt GA; Sullivan PG
    Exp Neurol; 2023 May; 363():114356. PubMed ID: 36841465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.
    Rekkas PV; Wilson AA; Lee VW; Yogalingam P; Sacher J; Rusjan P; Houle S; Stewart DE; Kolla NJ; Kish S; Chiuccariello L; Meyer JH
    JAMA Psychiatry; 2014 Aug; 71(8):873-9. PubMed ID: 24898155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.